Project description
Analytical platform for prioritisation of monoclonal antibodies and vaccines against antimicrobial resistance
Antimicrobial resistance (AMR) represents a major threat to human health and is increasing in all bacteria due to antibiotic-induced selection, transfer via genetic mobile elements, global transport, and environmental waste. To support the development of monoclonal antibodies and vaccines to fight against AMR, the EU/EFPIA-funded PrIMAVeRa aims to develop a web-based platform that combines mathematic modelling with a comprehensive epidemiological repository. Systematic updates will generate data to potentially enable the selection of suitable models for determining the AMR burden by pathogen, infection, target population and evaluate the effect of monoclonal antibodies and vaccines. Aspects of AMR will be explored by deterministic continuous-time models and stochastic discrete-time individual-based models with multiple modules. Bayesian analysis will be used for the economics assessment.
Objective
Antibiotic resistance (AMR), a major threat to human health, is increasing in all bacteria through antibiotic-induced selection, cross-species transfer of genetic mobile elements harbouring resistance genes, global transport and environmental waste. With an almost empty antibiotic pipeline, monoclonal antibodies (mAbs) and vaccines are increasingly recognized as important tools against AMR. Yet, available resources cannot finance all potential interventions, and choices need to be made according to costs of mAbs and vaccines, impact on the burden of AMR and prevention of its economic consequences. The PrIMAVeRa consortium will develop a web-based platform that combines advanced mathematical models with a comprehensive epidemiological repository. Systematic reviews will generate data to inform the model structure and parametrisation and select the most appropriate models for determining the AMR burden by pathogen, infection and target population. Deterministic continuous time models (ordinary differential equations [ODE]) and stochastic discrete time individual-based models with multiple modules will cover all relevant aspects of AMR, while Bayesian approaches will be used for cost-effectiveness analysis. The models will be calibrated in 8 EU countries based on the data coming from health information systems. The PrIMAVeRa consortium comprises a prominent collection of European research groups with expertise in AMR, vaccines, mAbs, mathematical and economical modelling. The proposal builds on established research collaborations and existing research infrastructures from EU- and IMI-funded research projects, such as EPI-Net (COMBACTE-MAGNET) and CLIN-Net and LAB-Net (COMBACTE-NET). The major deliverable will be an open access web-based user interface that will allow the wider scientific community to freely access and apply the models. This platform will also help healthcare authorities to make data-driven decisions on which vaccines and mAbs should be prioritised.
Fields of science
- natural sciencesbiological sciencesmicrobiologybacteriology
- natural sciencesmathematicspure mathematicsmathematical analysisdifferential equations
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
- natural sciencesmathematicsapplied mathematicsmathematical model
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
69115 Heidelberg
Germany
See on map
Participants (18)
3584 CX Utrecht
See on map
1211 Geneve
See on map
37129 Verona
See on map
2800 Kongens Lyngby
See on map
75724 Paris
See on map
41071 Sevilla
See on map
50161 KAUNAS
See on map
LS2 7UE Leeds
See on map
28029 Madrid
See on map
Participation ended
1230 Wien
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
38058 Grenoble
See on map
Participation ended
197101 Saint Petersburg
See on map
OX1 2JD Oxford
See on map
69115 Heidelberg
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
72074 Tuebingen
See on map
1330 Rixensart
See on map
CT13 9NJ Sandwich
See on map
2333 CN Leiden
See on map